Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Renal Cell Carcinoma: An Evolving Treatment Landscape

March 8th 2018

Immunotherapeutic Combinations for mRCC: IMmotion-151

March 8th 2018

Personal Approaches to Treating Brain Metastasis in RCC

March 8th 2018

Metastatic RCC: Selecting Therapy at Recurrence

March 8th 2018

Metastatic Renal Cell Carcinoma: When to Switch Therapy

March 8th 2018

Defining Recurrence in Patients With Metastatic RCC

March 8th 2018

Factors in Selecting Immunotherapy or TKI Inhibition

March 8th 2018

Metastatic RCC: Using Frontline Ipilimumab/Nivolumab

March 8th 2018

Evaluating Frontline Systemic Therapy for Metastatic RCC

March 8th 2018

Newly Diagnosed Metastatic RCC: Frontline Therapy

March 8th 2018

Perioperative RCC Treatment: Immunotherapy and Urology

March 8th 2018

RCC: Applying Adjuvant Therapy Data From Clinical Trials

March 8th 2018

Adjuvant Sunitinib's Role in the Treatment of RCC

March 8th 2018

Dr. Tripathy on Impact of Olaparib Approval in BRCA-Positive Breast Cancer

March 8th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of olaparib (Lynparza) for patients with BRCA-positive breast cancers and the impact it has had on clinical practice. Tripathy shared this insight in an interview during the 35th Annual Miami Breast Cancer Conference.

Research Strategies to Improve Outcomes in GBM

March 5th 2018

GBM Emerging Strategies in Immunotherapy

March 5th 2018

GBM Rationale for Combining PD1 Inhibitor DNA Vaccine

March 5th 2018

PD1 Inhibitor DNA Vaccine Combination Trial in GBM

March 5th 2018

DNA Vaccine Creating Immunogenicity in GBM

March 5th 2018

Efficacy of Checkpoint Inhibition in Glioblastoma

March 5th 2018